格隆汇1月16日丨荣昌生物(09995.HK)公告,公司预计2024年度营业收入约人民币171,500万元,与上年同期相比,将增加收入约人民币63,200万元,同比增加约58%。公司预计2024年度实现归属于母公司所有者的净亏损约人民币147,000万元,与上年同期相比,将减少亏损约人民币4,100万元,同比亏损减少约3%。公司预计2024年度归属于母公司所有者扣除非经常性损益后的净亏损约人民币...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.